Moleculin Biotech, Inc.MBRX
| Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
---|
Cash and cash equivalents | 5 | 8 | 7 | 11 | 15 | 71 | 43 |
---|
Prepaid expenses and other current assets | - | - | - | 3 | 2 | 2 | 2 |
---|
Total current assets | 5 | 8 | 8 | 13 | 17 | 72 | 46 |
---|
Furniture and equipment, net of accumulated depreciation of $769 and $638, respectively | 23,128 | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Intangible assets | 11 | 11 | 11 | 11 | 11 | 11 | 11 |
---|
Operating lease right-of-use asset | - | - | - | 0 | 0 | 0 | 0 |
---|
Total Assets | 16 | 19 | 20 | 25 | 29 | 84 | 57 |
---|
Accounts payable | - | 1 | 1 | 2 | 1 | 1 | 2 |
---|
us-gaap_AccruedLiabilitiesCurrent | - | 1 | 2 | 1 | 2 | 2 | 3 |
---|
Total current liabilities | 1 | 2 | 4 | 4 | 3 | 4 | 5 |
---|
Operating lease liability - long-term, net of current portion | - | - | - | 0 | 0 | 0 | 0 |
---|
Warrant liability - long-term | - | - | 1 | 6 | 8 | 1 | 0 |
---|
Total Liabilities | 1 | 2 | 5 | 10 | 11 | 5 | 5 |
---|
Preferred stock, $0.001 par value; 5,000,000 authorized, no shares issued and outstanding | - | - | - | - | - | - | - |
---|
Common stock, $0.001 par value; 100,000,000 authorized as of December 31, 2022 and December 31, 2021, 28,627,827 and 28,578,338 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 12,165 | 0 | 0 | 0 | 0 | 0 | 0 |
---|
Additional paid-in capital | 20 | 32 | 41 | 55 | 75 | 152 | 154 |
---|
Accumulated other comprehensive income | - | - | 0 | 0 | 0 | 0 | 0 |
---|
Accumulated deficit | -4,674,721 | -14 | -26 | -40 | -57 | -73 | -102 |
---|
Total stockholders' equity | 15 | 17 | 14 | 16 | 18 | 79 | 52 |
---|
Total liabilities and stockholders' equity | 16 | 19 | 20 | 25 | 29 | 84 | 57 |
---|